Loading organizations...
Discure Technologies is a medical technology company based in Herzliya, Israel, that develops a minimally invasive bioelectronic implant for treating degenerative disc disease. The outpatient device utilizes electrical stimulation to control fluid, nutrient, and oxygen inflow to the spinal disc, aiming to reduce pain and promote tissue regeneration with a 17-year battery life. The company targets a global population of over 400 million individuals suffering from discogenic low back pain, which accounts for 35% of chronic back pain cases. Operating with 1,001 to 5,000 employees, the enterprise has raised $11 million in total funding, including a Series A round backed by investors Bold Capital Partners and TSVC Capital. After receiving Breakthrough Device designation for the Discure System from the FDA in 2021, the firm continues advancing toward commercialization. Discure Technologies was founded in 2019 by Yuval Mandelbaum.
Discure Technologies has raised $11.0M across 1 funding round.
Discure Technologies has raised $11.0M in total across 1 funding round.
Discure Technologies Ltd. is a medtech company developing the Discure System, a bioelectronic implantable device for treating mid-stage degenerative disc disease (DDD), a primary cause of low back pain affecting over 35% of cases and up to 4 in 5 adults lifetime.[1][2][3] The minimally invasive, outpatient implant reduces pain, restores spine function, and promotes tissue regeneration by controlling fluid, nutrient, and oxygen inflow to the disc via electrical stimulation, with a 17-year battery life.[2][3] It targets patients underserved by current options like pain meds or invasive surgery, deployed by interventionalists or surgeons, and holds FDA Breakthrough Device designation since 2021, with De Novo approval projected in at least three years.[2]
Discure Technologies emerged to address the massive unmet need in DDD treatment, focusing on bioelectronic innovation for a condition causing persistent, debilitating low back pain that disrupts daily life.[3] Specific founding details like year or founders' backgrounds are not detailed in available sources, but the company's mission crystallized around reversing disc degeneration non-surgically, building on the 2021 FDA Breakthrough Device nod as a pivotal early validation.[2][3] Early momentum includes advancing the Discure System toward commercialization, positioning it as a game-changer in spine care.[1][2]
Discure rides the bioelectronics wave in medtech, shifting spine care from symptom management to disease modification amid rising DDD prevalence from aging populations and sedentary lifestyles.[2][3] Timing aligns with FDA's push for Breakthrough Devices to fast-track innovations, countering market forces like opioid crises and surgery backlogs.[2] By enabling outpatient regeneration, it influences the ecosystem toward precise, electronics-driven therapies, potentially reducing healthcare costs and expanding access for millions with low back pain.[1][3]
Discure is poised for De Novo FDA approval in the next 2-3 years, unlocking U.S. commercialization and scaling to global markets amid surging demand for non-opioid pain solutions.[2] Trends like AI-optimized neuromodulation and personalized implants will amplify its edge, evolving its role from DDD specialist to broader spine bioelectronics leader. As low back pain burdens healthcare systems, Discure's regenerative promise could redefine patient outcomes, tying back to its core mission of restoring millions to pain-free mobility.[3]
Discure Technologies has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $11M Series A | — | Bold Capital Partners, Tsvc Capital | Announced |
Discure Technologies has raised $11.0M in total across 1 funding round.
Discure Technologies's investors include Bold Capital Partners, TSVC Capital.
